Effect of intubation in the lateral position under general anesthesia induction on the position of double-lumen tube placement in patients undergoing unilateral video-assisted thoracic surgery: study protocol for a prospective, single-center, parallel group, randomized, controlled trial.

BACKGROUND: The double-lumen tube (DLT) is an essential equipment for thoracic anesthesia and the precise position of DLT placement is particularly important for anesthesia and surgery. However, the incidence of DLT malposition remains high and it leads to lung isolation failure and hypoxemia during one-lung ventilation. This trial aims to explore the clinical application and efficacy of intubation in the lateral position under general anesthesia induction to reduce the incidence of DLT malposition in patients undergoing unilateral video-assisted thoracic surgery (VATS). METHODS: In this prospective, single-center, parallel group, randomized, controlled trial, we will recruit 108 patients, aged 18-80 years, scheduled for elective unilateral VATS with DLT intubation under general anesthesia, and they will be randomly assigned to two groups: a lateral DLT intubation group (group L) and a conventional supine DLT intubation group (group C). The left-sided DLT will be used to intubate in patients of both groups. The position of DLT will be confirmed and adjusted by using the fiberoptic bronchoscopy (FOB). The primary outcome is the incidence of DLT malposition observed via the FOB, and the secondary outcomes include the time of intubation, the frequency and duration of re-adjustments of DLT placement under FOB, whether to re-intubate, intraoperative vital signs, and postoperative recovery. DISCUSSION: Accurate DLT positioning is crucially important for thoracic surgery, but the incidence of DLT malposition is still high in the present clinical practice of thoracic anesthesia. This trial aims to investigate whether lateral DLT intubation can reduce the incidence of DLT malposition, with more stable intraoperative vital signs and less postoperative complications. TRIAL REGISTRATION: The study protocol was registered at Chinese Clinical Trial Registry ( http://www.chictr.org.cn ) with registration number: ChiCTR2200060794 on June 11, 2022.

[Preparation of Two Kinds of Biochar and the Factors Influencing Tetracycline Removal from Aqueous Solution].

In this research, Chinese medicine residue of Evodia lepta and corn stalks were chosen as raw materials to prepare biochar (EIBC and CSBC) at 400, 600, and 800℃, for the removal of tetracycline from solution. The biochar was characterized by elemental analysis, Fourier transform infrared (FT-IR) spectroscopy, X-ray diffraction (XRD), and scanning electron microscopy (SEM). The effects of pyrolytic temperature, biochar dosages, initial concentration, adsorption time, solution pH, ionic strength, and ambient temperature on the removal of tetracycline from solutions by biochar were investigated. The adsorption behavior of tetracycline by biochar was investigated using adsorption kinetics and adsorption isotherms. The results showed that the adsorption capacity of biochar for tetracycline was elevated with increase in the pyrolysis temperature. The biochar prepared from Chinese medicine residue Evodia lepta at under 800℃ (EIBC800) had the best adsorption properties. Biochar dosages, solution pH, ionic strength, and adsorption time had significant effects on the adsorption of tetracycline by EIBC800 and CSBC800. In contrast, the effect of ambient temperature on tetracycline adsorption was a concentration-dependent process. The adsorption kinetics and isotherms of tetracycline onto EIBC800 and CSBC800 were all fitted to pseudo-second order models (R2 0.9540 and 0.8355) and to a Freundlich equation (R2 between 0.8991-0.9579 and 0.9736-0.9946), respectively. The adsorption process was mainly controlled by chemical reaction, and the tetracycline adsorption process was spontaneous and endothermic. Compared with the corn-stalk derived biochar, EIBC800 had better adsorption capacity for antibiotics than CSBC800 did, which indicated that Chinese medicine residue derived biochar had wider prospects for application in the treatment of wastewater containing antibiotic residues.

Upregulation of miR-1280 expression in non-small cell lung cancer tissues.

BACKGROUND: Non-small cell lung cancer (NSCLC) is a prolific and high-mortality disease with few effective treatments. Although the detection and surgical techniques for NSCLC continue to advance, the survival rate for the patients with NSCLC remains poor. Enhanced predictive biomarkers such as microRNAs (miRNAs) are needed at the time of diagnosis to better tailor therapies for patients. This study focused on the expression of miR-1280 in NSCLC tissues and distal normal tissues in order to explore the association between miR-1280 expression and NSCLC. METHODS: A total of 72 newly diagnosed primary NSCLC patients were enrolled in this study. Quantitative real-time polymerase chain reaction (PCR) was performed to identify the expression level of miR-1280 in the NSCLC tissues and distal normal tissues of these patients. RESULTS: The miR-1280 expression was significantly higher in the NSCLC tissues (0.084 ± 0.099) than distal normal tissues (0.014 ± 0.015, P = 0.009). In 54 patients (75%), the miR-1280 expression in the NSCLC tissues was upregulated (2-ΔΔct > 2), and no case showed a downregulation of miR-1280 expression. CONCLUSIONS: The expression level of miR-1280 could be regarded as a biomarker for NSCLC.